Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Anus Neoplasms 1

Interventions

Paclitaxel 41Specimen Handling 36Carboplatin 34pembrolizumab 32Bevacizumab 32Magnetic Resonance Spectroscopy 29olaparib 19liposomal doxorubicin 16Cisplatin 16Biopsy 16Gemcitabine 15Taxes 12Nivolumab 12Immunoglobulin G 11Disulfides 11Cyclophosphamide 11Topotecan 10Doxorubicin 10fludarabine 9niraparib 7mirvetuximab soravtansine 7Fulvestrant 7trastuzumab deruxtecan 6palbociclib 6durvalumab 6Surveys and Questionnaires 6Megestrol Acetate 6lenvatinib 5dostarlimab 5Radiation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diphenhydramine × Gynecologic × 30 days × Clear all
NCT04432597 2026-05-18

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
39 enrolled
GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡